StockNews.AI
IONS
StockNews.AI
195 days

Ionis to hold fourth quarter and full year 2024 financial results webcast

1. Ionis Pharmaceuticals will host a financial results webcast on February 19th. 2. The company has a strong pipeline in neurology, cardiology, and rare diseases. 3. Ionis is a pioneer in RNA-targeted medicines and gene editing. 4. It has six marketed medicines, showcasing its innovative capabilities. 5. The webcast will provide insights into Q4 and full-year 2024 results.

3m saved
Insight
Article

FAQ

Why Bullish?

The webcast may signal positive investor sentiment and financial performance expectations, similar to past successful presentations.

How important is it?

The webcast will likely influence investor perception and stock price based on financial outcomes.

Why Short Term?

Immediate reactions are expected during and after the webcast, aligning with earnings releases.

Related Companies

IONS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in innovative late- and mid-stage pipeline across our focus areas of neurology, cardiology and rare diseases. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Related News